Search
XL784
go.drugbank.com/drugs/DB04991InvestigationalXL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation.
Apadenoson
go.drugbank.com/drugs/DB05009InvestigationalApadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies.
Categories: Adenosine A receptor agonistsYSIL6
go.drugbank.com/drugs/DB05017ExperimentalYSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis.
Obinepitide
go.drugbank.com/drugs/DB05045ExperimentalObinepitide is a synthetic analogue of two natural human hormones, PYY and Pancreatic Polypeptide, which normally are released during a meal. … In obinepitide, the properties of both of these hormones have been implanted into a single molecule.
MB-07803
go.drugbank.com/drugs/DB05053InvestigationalMB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.
AN0128
go.drugbank.com/drugs/DB05054InvestigationalAN0128 is a novel compound that contains a boron atom within a borinic acid complex. … AN0128 is a good candidate for a topical antibiotic and is currently being developed by Anacor as a novel therapeutic for acne and atopic dermatitis.
SLV319
go.drugbank.com/drugs/DB05077ExperimentalSLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.
HY10275
go.drugbank.com/drugs/DB05079ExperimentalHY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process.
FP0011
go.drugbank.com/drugs/DB05090ExperimentalFP0011 is a small molecule antiglutamatergic compound with symptomatic and disease modifying effects in a variety of neurological disorders (amyotrophic lateral sclerosis and Parkinson's disease).
Matuzumab
go.drugbank.com/drugs/DB05101InvestigationalMatuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. … It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.